Table 1 Baseline characteristics of MDR-TB/HIV co-infected adults based on exposure to ART before/after the commencement of MDR-TB treatment

Age

36 (31–43)*

35.5 (31–42)*

0.557^b

Sex

 Male

264 (48.4)

193 (48.0)

0.896^c

 Female

281 (51.6)

209 (52.0)

 Category I (New)

107 (19.6)

107 (26.6)

0.026*^c

 Category II

438 (80.4)

295 (73.4)

 Negative

166 (30.5)

134 (33.3)

0.595^b

 Positive

317 (58.2)

221 (55.0)

 Not available

62 (11.4)

47 (11.7)

Site of TB

 Pulmonary

432 (79.3)

346 (86.1)

0.007*^c

 Extra-Pulmonary + Pulmonary

113 (20.7)

56 (13.9)

 Severely Underweight (<16)

68 (15.4)

41 (11.4)

0.174^c

 Underweight (≥16–18.49)

130 (29.4)

111 (31.0)

 Normal (≥18.5–24.99)

195 (44.1)

176 (49.2)

 Overweight/ obese (25–29.99)

49 (11.1)

30 (8.4)

 No

21 (4.4)

32 (9.7)

0.003*^c

 Yes

459 (95.6)

297(90.3)

CD4 cell count (mls/mm³)

160.5 (89–270)^a

156 (66–257)^a

0.1906^b

 <150

241 (46.5)

187 (48.1)

0.296^c

 150–349

209 (40.4)

140 (36.0)

 ≥350

68 (13.1)

62 (15.9)

Haemoglobin (g/dl)

11.3 (2.4)*

10.8(2.2)*

0.0012*^d

 Severe Anaemia (<7.0)

24 (4.5)

13 (3.3)

0.009*^c

 Moderate Anaemia (7.0–9.9)

120 (22.3)

123 (31.0)

 Mild Anaemia (10–10.99)

85 (15.8)

70 (17.7)

 Normal (≥11)

308 (57.4)

190 (48.0)

Duration on ART

218 (70–570)^b

57.5 (32–111.5)^b

Outcome duration or Person time (days)

251 (90–725)^b

720 (330–945)^b

0.0286*^b

Treatment-initiation-delay

11 (5–22)^b

10 (6–21)^b

0.921^b

 No

24 (4.5)

11 (2.8)

0.179^c

 Yes

513 (95.5)

385 (97.2)

 No

315 (58.7)

237 (59.8)

0.715^b

 Yes

222 (41.3)

159 (40.2)

 No

77 (14.3)

58 (14.7)

0.883^c

 Yes

460 (85.7)

337 (85.3)

 No

399 (73.4)

228 (57.1)

<0.001*^c

 Yes

145 (26.6)

171 (42.9)

Comorbidity

 No

461 (85.8)

345 (88.0)

0.337^c

 Yes

76 (14.2)

47 (12.0)

Adverse events

 No

295 (54.8)

239 (61.1)

0.055^c

 Yes

243 (45.2)

152 (38.9)

 Standardised

370 (68.5)

295 (75.1)

0.029*^c

 Modified individualised

170 (31.5)

98 (24.9)